Table 2.
Intervention characteristics
| Author (year) | Source of MSCs | Comparison | MSCs | Timing | Dosage and volume |
|---|---|---|---|---|---|
| Route, condition | |||||
| Acute myocardial infarction | |||||
| Chen (2004) | Autologous | Saline | IC, Fresh | 18 ± 0.5 days post‐PCI | 8–10 × 109,1 dose – NR |
| Chullikana (2015) | Allogeneic | Plasmalyte A | IV, Fresh from cryopreserved | 2 days post‐PCI | 2 million cells/kg, 1 dose – 0.5 mL/kg |
| Gao (2013) | Autologous | Standard treatment | IC, Fresh | Post‐PCI Mean 17 ± 1 days |
3 ± 0.5 × 1061 dose – 10 mL |
| Gao (2015) | Allogeneic | Heparanized saline | IC, Fresh | Within 5–7 days of PCI | 6 × 106, 1 dose – 10 mL |
| Hare (2009) | Allogeneic | Placebo | IV, NR | Patients randomized 1–10 days post AMI | 0.5, 1.6, 5 × 106
3 dose escalation cohorts ‐ NR |
| Houtgraaf (2012) | Autologous | Placebo | IC, Fresh | 24 hours post‐PCI | 17.4 ± 4.1 × 106
1 dose ‐ NR |
| Lee (2014) | Autologous | Standard treatment | IC, Fresh | BM aspiration done 4 ± 2 days post‐admission; culture took 25.0 ± 2 days | 7 ± 1 × 107
1 dose ‐ NR |
| Musialek (2015) | Allogeneic | No comparison | IC, Fresh from cyropreserved | Within 5–7 days of PCI | 30 × 106
1 dose – 30 mL |
| Rodrigo (2013) | Autologous | Historical control | IM, Fresh | 21 ± 3 days post‐MI/PCI | 31 ± 2 × 106
1 dose – 5 mL |
| Wang (2014) | Autologous | Saline | IC, Fresh | 14 days post‐PCI | 2 × 108
1 dose – 2 mL |
| Yang (2010) | Autologous | No comparison | IC, Fresh | NR | 1 ± 2 × 107
1 dose ‐ NR |
| Ischemic heart failure | |||||
| Bartunek (2017) | Autologous | Sham procedure | IM, Frozen | NR | NR 1 dose – 0.5 mL |
| Chen (2006) | Autologous | Standard treatment | IC, Fresh | BM aspiration done 8 days post‐PCI; culture for 7 days | 5 × 106, 1 dose – NR |
| Guijarro (2016) | Autologous | No comparison | IV, Fresh | NR | 40 × 106
1 dose – 2‐3 mL |
| Hare (2012) | Allogeneic | Autologous | EC, NR | NR | 0.2, 1, 2 × 108
3 dose cohorts – 5.0 mL each |
| Heldman (2014) | Autologous | Placebo | EC, Fresh from cyropreserved | During cardiac catheterization. Mean time since first MI is 10 ± 10 years. | 2 × 108
1 dose – 5.0 mL |
| Karantalis (2014) | Autologous | Placebo | EP, Fresh from cyropreserved | Post‐CABG; mean time between last MI and study enrollment was 675 days | 2 × 107 or 2 × 108
1 dose – 5.0 mL |
| Li (2015) | Allogeneic | No comparison | IC, Fresh | NR | 3, 4, or 5 × 106
1 dose – NR |
| Mathiasen (2013) | Autologous | No comparison | IM, unclear | NR | Mean 22 × 106
1 dose ‐ NR |
| Mathiasen (2015) | Autologous | Saline | IM, Fresh | NR | Mean 78 ± 68 × 106
1 dose – 2–3 mL |
| Viswanathan (2010) | Autologous | Standard treatment | EP, Fresh from cryopreserved | During CABG; BM culture took 3–4 weeks | 3 × 106 to 26 × 106
1 dose – 1 mL |
| Wang (2006) | Autologous | Saline | IC, Fresh | NR | NR 1 dose – 30 mL |
| Zhao (2015) | Allogeneic | Standard treatment | IC, unclear | NR | NR 1 dose – 20 mL |
Dose is provided as reported by the study or the mean ± SD number of cells delivered to patients. Abbreviations: C, control groups; EC, endocardial; EP, epicardial; FBS, Fetal Bovine Serum; HSA, Human Serum Albumin; IC, intracoronary; IM, intramyocardial; IV, intravenous; MSCs, mesenchymal stromal cells; NR, not reported; NRCT, non‐randomized controlled trial; PCI, percutaneous coronary intervention; RCT, randomized controlled trial; T, treatment group.